Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System
Little is known about tumor-related prognostic factors, in particular specific chromosomal abnormalities, in young patients with multiple myeloma (MM). We therefore investigated the chromosomal pattern by interphase fluorescence in situ hybridization (chromosomes 13q14, 14q32-translocations, chromosomes associated with hyperdiploidy) in 38 young patients with MM (age <45 yr) and compared the results with those observed in 69 patients with intermediate age (45–70 yr) and 64 elderly patients (age >70 yr). All chromosomal patterns were not significantly different between the three age cohorts. Similarly, standard MM parameters were equally distributed between these MM patient populations. However, survival by the International Staging System (ISS) for MM revealed marked differences between stage I/II (median survival not yet reached) and stage III (23.4 months; P < 0.0003) among young MM patients. A significant survival difference between ISS-stage I/II and ISS-stage III patients was also noted in the intermediate age group (median 65.4 months vs. 24.6 months; P = 0.0009). However, this difference disappeared among elderly MM patients (39.6 months in ISS-stage I/II vs. 32 months in ISS-stage III patients; P = 0.94), but it was unrelated to the cytogenetic pattern. Our results indicate that MM in young patients does not represent a distinct biologic entity, and that short survival of younger MM patients at ISS-stage III is independent of the molecular cytogenetic pattern.
Document Type: Research Article
Affiliations: 1: Department of Internal Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna 2: Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna 3: Department of Internal Medicine I, Bone Marrow Transplant Unit, Medical University of Vienna, Vienna 4: Department of Medicine I, Cente of Oncology and Hematology, Wilhelminenspital, Vienna 5: Department of Internal Medicine III and Ludwig-Boltzmann-Institute for Leukemia Research and Hematology, Hanuschspital, Vienna, Austria
Publication date: 01 March 2007